Specgx Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SPECGX LLC, and what generic alternatives to SPECGX LLC drugs are available?
SPECGX LLC has sixty-one approved drugs.
There is one US patent protecting SPECGX LLC drugs.
There are ten patent family members on SPECGX LLC drugs in nine countries and thirty supplementary protection certificates in ten countries.
Summary for Specgx Llc
International Patents: | 10 |
US Patents: | 1 |
Tradenames: | 47 |
Ingredients: | 31 |
NDAs: | 61 |
Drug Master File Entries: | 73 |
Drugs and US Patents for Specgx Llc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Specgx Llc | ACETAMINOPHEN AND CODEINE PHOSPHATE | acetaminophen; codeine phosphate | TABLET;ORAL | 040419-002 | May 31, 2001 | AA | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Specgx Llc | LISDEXAMFETAMINE DIMESYLATE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 211840-006 | Aug 25, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Specgx Llc | MORPHINE SULFATE | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 076412-003 | Jul 31, 2003 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Specgx Llc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Specgx Llc | EXALGO | hydromorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021217-004 | Aug 24, 2012 | 5,914,131 | ⤷ Try a Trial |
Specgx Llc | EXALGO | hydromorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021217-002 | Mar 1, 2010 | 5,914,131 | ⤷ Try a Trial |
Specgx Llc | PAMELOR | nortriptyline hydrochloride | CAPSULE;ORAL | 018013-001 | Approved Prior to Jan 1, 1982 | 3,922,305 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SPECGX LLC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Oral Solution | 5 mg/5 mL and 10 mg/5 mL | ➤ Subscribe | 2010-04-13 |
International Patents for Specgx Llc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 1867359 | ⤷ Try a Trial |
Australia | 2004280240 | ⤷ Try a Trial |
European Patent Office | 1680144 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Specgx Llc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2316456 | SPC/GB17/078 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE.; REGISTERED: UK EU/1/14/988 20150330; UK PLGB 50742/0001 20150330 |
1644019 | 301019 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: LISDEXAMFETAMINE, DESGEWENST IN DE VORM VAN EEN MESYLAAT- OF HYDROCHLORIDEZOUT DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 124498 20190528; FIRST REGISTRATION: GB PL 08081/0050-52 20130201 |
1644019 | LUC00189 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LISDEXAMFETAMINE, OPTIONALLY IN THE FORM OF A MESYLATE OR HYDROCHLORIDE SALT THEREOF; AUTHORISATION NUMBER AND DATE: PL08081/0050-52 20200901 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.